(NASDAQ: LTRN) Lantern Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.6%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.33%.
Lantern Pharma's earnings in 2025 is -$19,877,186.On average, 1 Wall Street analyst forecast LTRN's earnings for 2025 to be -$19,520,352, with the lowest LTRN earnings forecast at -$19,520,352, and the highest LTRN earnings forecast at -$19,520,352. On average, 1 Wall Street analyst forecast LTRN's earnings for 2026 to be -$12,294,587, with the lowest LTRN earnings forecast at -$12,294,587, and the highest LTRN earnings forecast at -$12,294,587.
In 2027, LTRN is forecast to generate -$17,471,255 in earnings, with the lowest earnings forecast at -$17,471,255 and the highest earnings forecast at -$17,471,255.